M

Merck

Makes medicines, vaccines and animal treatments

Executive Director - Multiple Teams

Full-TimeUpdated on 10/16/2026Deadline 11/6/26
$310.9k - $489.4k+ Annual bonus + Long-term incentive
Expert
MD
Boston, MA, USA+2 moreMore locations: Upper Gwynedd Township, PA, USA | Rahway, NJ, USA
HybridHybrid work arrangement.
Biology & BiotechClinical Research Operations
H1B Sponsorship Available

About the job

Requirements
  • An M.D. or M.D./Ph.D. is required.
  • At least 3 years of clinical medicine experience is required.
  • At least 5 years of industry experience in drug development, with demonstrated success overseeing multiple studies and protocols through completion, is required.
  • Experience authoring regulatory documents and leading discussions with regulatory agencies is required.
  • A demonstrated record of scientific scholarship and achievement is required.
  • A proven track record in clinical medicine and a background in biomedical research are required.
  • Strong interpersonal and collaborative skills and the ability to function in a matrix environment are required.
  • The ability to deliver clear, impactful communication verbally, in writing, and during presentations is required.
  • Required skills include clinical development, clinical judgment, clinical medicine, clinical trial development, ethical standards, hematology, intellectual curiosity, interdisciplinary problem solving, lymphoma, mentorship, program strategy, regulatory compliance, scientific leadership, senior program management, and strategic planning.
Responsibilities
  • Plan and direct clinical research activities involving new or marketed medicines in Oncology, Hematology.
  • Manage and oversee late-stage clinical development from Phase 2 to Phase 5, including program strategy and design, protocol authoring, initiation, execution, monitoring, analysis, regulatory reporting, publication, and presentation at national and international meetings.
  • Lead cross-functional product development teams overseeing program strategy and execution, provide internal scientific leadership for cross-functional areas supporting clinical trials, and interact externally with key scientific leaders.
  • Evaluate pre-clinical and translational work to generate early clinical development plans and Investigational New Drug applications.
  • Develop clinical development strategies for investigational or marketed medicines using scientific developments, regulatory requirements, the competitive landscape, and commercial considerations.
  • Execute clinical strategy, plan clinical trials, including design, operational plans, and settings, and lead the clinical subteam.
  • Monitor and manage the conduct of ongoing or new clinical trials for investigational or marketed medicines.
  • Integrate cross-functional input and expertise, ensure all perspectives are included in the strategy and plan, and serve as the product development team spokesperson.
  • Analyze and summarize clinical findings from studies to support safety and efficacy decisions, new drug applications, clinical study reports, and publications.
  • Participate in internal and joint internal/external research project teams relevant to developing new compounds and further studying marketed compounds.
  • Support business development assessments of external opportunities.
  • Manage Clinical Directors and/or Senior Clinical Directors responsible for clinical development work, demonstrating effective leadership and fostering a high-performance culture.
  • Work with experts in commercialization, regulatory affairs, statistics, and manufacturing to manage clinical development projects; assist the Associate Vice President and/or Vice President in informing appropriate Corporate personnel of study progress, competitor drugs, and internal and external expert opinion on relevant scientific questions.
  • Lead internal governance presentations to senior management and committees, communicate progress and key changes in product development strategy between stage gates, ensure early alignment with line management, and facilitate issue escalation and cross-functional collaboration for governance approval.
  • Maintain awareness of scientific developments, new findings, and research methodologies within the area of expertise.
  • Identify scientifically and operationally strong investigators who can assist in developing investigational and marketed drugs.
  • Establish communications with prominent clinical investigators who can assist in evaluating the company's drugs.
  • Attend scientific meetings to maintain competency and awareness of research activities in the area of responsibility.
  • Author and/or oversee detailed development documents, presentations, budgets, and position papers for internal and external audiences.
  • Facilitate collaborations with external researchers around the world.
  • Travel on company business to manage future or ongoing clinical research projects.
Desired Qualifications
  • Board certification or eligibility in Oncology, Hematology, or a related discipline is preferred.
  • Lymphoma experience is preferred.
  • Prior clinical research experience and a prior publication record are preferred.
  • Product registration experience is desirable.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

WebBizMarket
Oct 19th, 2026
Cancer vaccine manufacturing time could shrink.

Cancer vaccine manufacturing time could shrink. Merck's CEO Rob Davis expressed optimism regarding the manufacturing timeline of the company's cancer vaccine developed in collaboration with Moderna. In a recent interview with CNBC, Davis indicated that efforts are being made to shorten the current six-week production period, which could improve patient access to this innovative treatment. The vaccine is personalized, targeting mutations specific to each patient's tumor, which complicates production but is designed to enhance the immune system's ability to combat cancer. Davis emphasized the complexity of the vaccine manufacturing process but conveyed confidence in the collaboration between Merck and Moderna, stating that they have refined the process to ensure timely delivery to patients. Positive preliminary data from a late-stage trial involving melanoma patients has bolstered this optimism, with ongoing investigations into the vaccine's efficacy against other cancers, including non-small cell lung cancer and bladder cancer. In a related development, Merck has inaugurated a new 120,000-square-foot research facility named Advance at its West Point, Pennsylvania campus. This facility incorporates advanced technology aimed at enhancing research and development processes. The launch comes as Merck anticipates the expiration of patents for its flagship drug, Keytruda, which is essential to its revenue model. To mitigate potential revenue loss, the company plans to bolster its pipeline with both internal research and substantial external acquisitions. Merck is also addressing legal challenges regarding the subcutaneous formulation of Keytruda in Europe, where a recent court ruling has affected its market capabilities. Despite these hurdles, the company remains focused on introducing new therapies, including its recently approved cholesterol-lowering medication, Lipfendra. Why this story matters * This vaccine represents a significant advancement in personalized cancer treatment, potentially improving patient outcomes. Key takeaway * Merck and Moderna are committed to refining the manufacturing process of their personalized cancer vaccine, aiming for broader patient access. Opposing viewpoint * Legal challenges regarding Keytruda's subcutaneous formulation could hinder market penetration and affect future revenues.

Spot On Pennsylvania
Oct 16th, 2026
Merck expands near philadelphia as riverside plant winds down.

Merck expands near philadelphia as riverside plant winds down. RIVERSIDE - While Merck is closing its longtime manufacturing operation in Northumberland County, the pharmaceutical company is preparing a major expansion elsewhere in Pennsylvani... Discover more Get Sports Gear Discover more Read Daily News